

Vidac Pharma Holding PLC Announces Participation in the First Pediatric Brain Tumor Research Conference In Jerusalem

Vidac Pharma Holding Plc. is pleased to announce its participation in the First Pediatric Brain Tumor Research Meeting on March 9, 2025, in Jerusalem, Israel

LONDON, UNITED KINGDOM, March 4, 2025 /EINPresswire.com/ -- This landmark event will bring together leading international researchers, clinicians, and industry experts to share insights and advancements in pediatric brain tumor research. Dr.

Herzberg will present findings from Vidac Pharma's latest breakthrough, underscoring the company's commitment to developing innovative treatment approaches.



As part of a compassionate treatment program for a five-year-old child, Vidac Pharma's investigational drug VDA-1102 was successfully formulated to cross the blood-brain barrier (BBB) and was detected within the tumor at potentially therapeutic concentrations. "This marks a significant milestone, opening new possibilities for groundbreaking therapies targeting brain diseases," said Dr. Herzberg. "Our discovery represents an exciting opportunity to transform treatment options for children battling these devastating conditions, while Vidac Pharma remains dedicated to advancing clinical programs in oncodermatology."

“

Our discovery represents the opportunity to transform treatment options for children battling these devastating conditions, while we remain dedicated to advancing clinical programs in Oncodermatology”

Dr. Max Herzberg

+972 54-425-7381

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/790546339>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.